

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING BY SUBSTANTIAL SHAREHOLDERS

Consun Pharmaceutical Group Limited (the “**Company**”) was informed by Mr. AN Yubao and Ms. LI Qian, each an executive director and a substantial shareholder of the Company, that during the period from 26 January 2016 to 29 January 2016, Ms. LI Qian (through herself and/or her holding companies) and Mr. AN Yubao acquired a total of 2,730,000 and 1,118,000 shares of the Company in the open market, for a total consideration of approximately HK\$11,478,000 and HK\$4,759,000, respectively (the “**Acquisition**”).

Immediately after the Acquisition, Ms. LI Qian and Mr. AN Yubao through themselves and their respective holding companies were interested in a total of 137,852,261 and 214,765,817 shares of the Company, respectively, representing approximately 13.82% and 21.52% of the total issued share capital of the Company.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 1 February 2016

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong as non-executive Director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.